Meeting
2011 ASCO Annual Meeting
A phase I study of the AKT inhibitor (MK-2206) with concurrent trastuzumab and lapatinib in patients with HER2-positive solid tumors.
Authors
H. S. Han
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
H. S. Han , C. Swanton , Y. Y. Janjigian , S. C. Sutherland , S. Chandarlapaty , R. Lehman , N. Hamilton , J. Knowles , R. Lee , L. Yan , D. Sullivan , C. Hudis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics - Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
PI3-Akt-mTOR Pathway
Clinical Trial Registration Number
NCT00963547
Citation
J Clin Oncol 29: 2011 (suppl; abstr 3028)
Abstract #
3028
Poster Bd #
18
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A phase I study of MK-2206 in combination with lapatinib in patients (pts) with advanced solid tumors.
First Author: Kari Braun Wisinski
Poster
2012 ASCO Annual Meeting
A phase I study of S-222611 an oral reversible dual inhibitor of EGFR and HER2, in patients with solid tumors.
First Author: Richard D Baird
Poster
2017 ASCO Annual Meeting
Proof-of concept phase I study of everolimus, letrozole and trastuzumab in hormone receptor-positive, HER2-positive/amplified or mutant metastatic breast cancer or other solid tumors: Evaluating synergy and overcoming resistance.
First Author: Shubham Pant
Poster
2014 ASCO Annual Meeting
Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in participants with brain metastases from HER2+ breast cancer.
First Author: Otto Metzger-Filho